JTCS Tips for Better Browsing
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Miguel Josa
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Muxí, A.
Right arrow Articles by Bosch, X.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Muxí, A.
Right arrow Articles by Bosch, X.
Related Collections
Right arrow Cardiac - other
Right arrow Coronary disease
Right arrow Minimally invasive surgery

J Thorac Cardiovasc Surg 2003;125:1493-1498
© 2003 The American Association for Thoracic Surgery

Cardiopulmonary Support and Physiology

Technetium 99m-labeled tetrofosmin and iodine 123-labeled metaiodobenzylguanidine scintigraphy in the assessment of transmyocardial laser revascularization

Africa Muxí, MDa,b, Jordi Magriñá, MDc, Francisco Martín, MDa, Miguel Josa, MDc, David Fuster, MDa,b, Francisco J. Setoain, MDa, Félix Pérez-Villa, MDc, Javier Pavía, PhDa,b, Xavier Bosch, MDb,c

From Servei de Medicina Nuclear (Centre de Diagnóstic per la Imatge),a Hospital Clínic, Universitat de Barcelona; Institut d'Investigacions Biomèdiques August Pí I Sunyer (IDIBAPS),b Institut de Malalties Cardiovasculars,c Barcelona, Spain.

Supported by a grant from Fondo de Investigaciones Sanitarias (FIS 99-316) and in part by an unrestricted grant from Bayer.

Received for publication Jan 22, 2002. Revisions requested April 30, 2002; revisions received May 22, 2002. Accepted for publication Aug 6, 2002. Address for reprints: Africa Muxí, MD, Nuclear Medicine Department, Hospital Clínic, Villarroel 170, 08036 Barcelona, Spain (E-mail: amuxi{at}clinic.ub.es).

Objective: Transmyocardial laser revascularization is a new technique that improves symptoms in patients with refractory angina not amenable to conventional revascularization. The aim of this study was to assess whether transmyocardial laser revascularization produces changes in innervation, perfusion scintigraphy, or both that could explain the benefit to patients.
Methods: Sixteen patients (12 men and 4 women; mean age, 60 ± 8 years) with coronary artery disease were studied. Transmyocardial laser revascularization was performed in 39 myocardial areas supplied by a stenotic vessel. A technetium 99m-labeled tetrofosmin stress-rest tomographic scan and iodine 123-labeled metaiodobenzylguanidine planar scans were performed before and after transmyocardial laser revascularization (3 and 12 months later) to evaluate myocardial perfusion and innervation. Stress and rest perfusion images were quantified on a polar map. Ischemia uptake was also defined as the difference between rest and stress uptake for each area. Innervation planar images were visually analyzed and semiquantified.
Results: A significant decrease in angina class from baseline was observed at 3, 6, and 12 months after transmyocardial laser revascularization (P < .005). A significant decrease in ischemia uptake was also found between the pre-transmyocardial laser revascularization and the post-transmyocardial laser revascularization studies in treated areas (P < .001). A significant improvement in stress myocardial perfusion at 3 and 12 months after transmyocardial laser revascularization was only found in treated areas that were considered ischemic in the pre-transmyocardial laser revascularization study (P < .05). At 3 months, a significant myocardial innervation worsening was observed in treated areas (P < .001), with partial recovery at 12 months (P < .05).
Conclusion: The transmyocardial laser revascularization mechanism involves both perfusion improvement and denervation, mainly at 3 months, that partially recovered at 12 months.




This article has been cited by other articles:


Home page
 Ann. Thorac. Surg.Home page
T. Asai, S. Yamamoto, K. Ishino, T. Kohmoto, M. Kuriyama, G. Kato, Y. Oshima, N. Yamamoto, K. Notohara, S. Okada, et al.
Time-Dependent Regional Myocardial Denervation as a Nonspecific Response to Transmyocardial Laser Revascularization
Ann. Thorac. Surg., October 1, 2005; 80(4): 1362 - 1369.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2003 by The American Association for Thoracic Surgery.